Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension

Yohei Miura; Masaharu Kataoka; Tomohiro Chiba; Takumi Inami; Hideaki Yoshino; Toru Satoh

doi:10.1253/circj.CJ-18-0349

This article has now been updated. Please use the final version.

Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension

Yohei Miura, Masaharu Kataoka, Tomohiro Chiba, Takumi Inami, Hideaki Yoshino, Toru Satoh

Author information

Keywords: Epoprostenol, Giant fold gastritis, Pulmonary arterial hypertension, Stomach barium examination

JOURNAL FREE ACCESS FULL-TEXT HTML Advance online publication

Article ID: CJ-18-0349

DOI https://doi.org/10.1253/circj.CJ-18-0349

The final version of this article is now available: Vol. 82 (2018), No. 10 pp. 2676-2677

Details

Abstract

Background:Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol.

Methods and Results:The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019).

Conclusions:Giant fold gastritis may be an important side effect of epoprostenol infusion.

Corresponding author

Register with J-STAGE for free!